0001653606 2025-01-01 2025-12-31 0001653606 dei:BusinessContactMember 2025-01-01 2025-12-31 0001653606 2025-12-31 0001653606 2024-12-31 0001653606 us-gaap:RelatedPartyMember 2025-12-31 0001653606 us-gaap:RelatedPartyMember 2024-12-31 0001653606 us-gaap:NonrelatedPartyMember 2025-12-31 0001653606 us-gaap:NonrelatedPartyMember 2024-12-31 0001653606 2024-01-01 2024-12-31 0001653606 us-gaap:CommonStockMember 2023-12-31 0001653606 EHVVF:EquityPayableMember 2023-12-31 0001653606 us-gaap:RetainedEarningsMember 2023-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001653606 EHVVF:TotalShareholdersEquityMember 2023-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2023-12-31 0001653606 2023-12-31 0001653606 us-gaap:CommonStockMember 2024-12-31 0001653606 EHVVF:EquityPayableMember 2024-12-31 0001653606 us-gaap:RetainedEarningsMember 2024-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001653606 EHVVF:TotalShareholdersEquityMember 2024-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2024-12-31 0001653606 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001653606 EHVVF:EquityPayableMember 2024-01-01 2024-12-31 0001653606 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001653606 EHVVF:TotalShareholdersEquityMember 2024-01-01 2024-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-12-31 0001653606 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001653606 EHVVF:EquityPayableMember 2025-01-01 2025-12-31 0001653606 us-gaap:RetainedEarningsMember 2025-01-01 2025-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-12-31 0001653606 EHVVF:TotalShareholdersEquityMember 2025-01-01 2025-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-12-31 0001653606 us-gaap:CommonStockMember 2025-12-31 0001653606 EHVVF:EquityPayableMember 2025-12-31 0001653606 us-gaap:RetainedEarningsMember 2025-12-31 0001653606 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001653606 EHVVF:TotalShareholdersEquityMember 2025-12-31 0001653606 us-gaap:NoncontrollingInterestMember 2025-12-31 0001653606 EHVVF:RejuvIVIncMember 2025-12-31 0001653606 EHVVF:AiboticsIncMember 2025-12-31 0001653606 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-01-01 2025-12-31 0001653606 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-01-01 2024-12-31 0001653606 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-12-31 0001653606 EHVVF:MedicalEquipmentMember 2025-12-31 0001653606 EHVVF:MedicalEquipmentMember 2024-12-31 0001653606 EHVVF:MajorShareholderMember 2024-01-30 0001653606 EHVVF:MajorShareholderMember EHVVF:MajorShareholderMember 2024-01-30 0001653606 EHVVF:MajorShareholderMember 2024-01-30 2024-01-30 0001653606 EHVVF:MajorShareholderMember 2025-01-01 2025-12-31 0001653606 EHVVF:MajorShareholderMember 2024-01-01 2024-12-31 0001653606 EHVVF:MajorShareholderMember 2025-12-31 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2021-01-01 2021-01-01 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2025-12-31 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2024-12-31 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2025-01-01 2025-12-31 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2024-01-01 2024-12-31 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2019-06-23 2019-06-24 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2019-06-29 0001653606 EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2020-04-16 0001653606 EHVVF:BenjaminKaplanMember 2020-12-31 0001653606 EHVVF:BenjaminKaplanMember 2020-01-01 2020-12-31 0001653606 srt:MinimumMember EHVVF:BenjaminKaplanMember EHVVF:ExecutiveConsultingAgreementMember 2020-01-01 2020-12-31 0001653606 EHVVF:BenjaminKaplanMember 2024-01-01 2024-12-31 0001653606 EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:JamesCardwellMember EHVVF:ConsultingAgreementMember 2020-10-01 2020-10-01 0001653606 EHVVF:JamesCardwellMember EHVVF:ConsultingAgreementMember 2025-12-31 0001653606 EHVVF:JamesCardwellMember EHVVF:ConsultingAgreementMember 2024-12-31 0001653606 us-gaap:ServiceMember EHVVF:ChiefTechonologyOfficerMember EHVVF:ExecutiveEmploymentAgreementMember 2020-01-01 2020-01-01 0001653606 EHVVF:ChiefTechonologyOfficerMember EHVVF:ExecutiveEmploymentAgreementMember 2025-12-31 0001653606 EHVVF:ChiefTechonologyOfficerMember EHVVF:ExecutiveEmploymentAgreementMember 2024-12-31 0001653606 EHVVF:EBITDAMilestonesOneMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:EBITDAMilestonesOneMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:EBITDAMilestonesTwoMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:EBITDAMilestonesTwoMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:EBITDAMilestonesThreeMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:EBITDAMilestonesThreeMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:EBITDAMilestonesFourMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:EBITDAMilestonesFourMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:EBITDAMilestonesFiveMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:EBITDAMilestonesFiveMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesOneMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesOneMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesTwoMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesTwoMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesThreeMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesThreeMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesFourMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesFourMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesFiveMember EHVVF:BenjaminKaplanMember 2025-12-31 0001653606 EHVVF:MarketCapitalizationMilestonesFiveMember EHVVF:BenjaminKaplanMember 2025-01-01 2025-12-31 0001653606 us-gaap:IntellectualPropertyMember 2024-11-28 0001653606 us-gaap:PreferredStockMember EHVVF:AiboticsIncMember 2025-01-01 2025-12-31 0001653606 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember EHVVF:AiboticsIncMember 2025-01-01 2025-12-31 0001653606 us-gaap:CommonStockMember EHVVF:AssetPurchaseAgreementMember 2025-05-23 2025-05-23 0001653606 us-gaap:PreferredStockMember EHVVF:AssetPurchaseAgreementMember 2025-05-23 2025-05-23 0001653606 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001653606 EHVVF:MilestoneOneMember 2025-01-01 2025-12-31 0001653606 EHVVF:MilestoneTwoMember 2025-01-01 2025-12-31 0001653606 EHVVF:MilestoneThreeMember 2025-01-01 2025-12-31 0001653606 EHVVF:MilestoneFourMember 2025-01-01 2025-12-31 0001653606 EHVVF:MilestoneFiveMember 2025-01-01 2025-12-31 0001653606 2024-12-13 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2025-05-06 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2025-05-06 2025-05-06 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2025-12-31 0001653606 EHVVF:VariousHoldersMember EHVVF:ConvertiblePromissoryNoteMember 2025-12-31 0001653606 EHVVF:VariousHoldersMember EHVVF:ConvertiblePromissoryNoteMember 2024-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2025-01-01 2025-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2024-01-01 2024-12-31 0001653606 EHVVF:PromissoryNoteMember 2025-09-12 0001653606 EHVVF:PromissoryNoteMember 2025-09-12 2025-09-12 0001653606 EHVVF:PromissoryNoteMember 2025-01-01 2025-12-31 0001653606 EHVVF:PromissoryNoteMember 2025-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2023-12-31 0001653606 EHVVF:ConvertiblePromissoryNoteMember 2024-12-31 0001653606 EHVVF:CollaborationAgreementMember 2025-12-31 0001653606 EHVVF:CollaborationAgreementMember 2024-12-31 0001653606 EHVVF:ConsultingAgreementMember 2021-11-15 2021-11-16 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2020-01-01 2020-12-31 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2025-01-01 2025-12-31 0001653606 us-gaap:CommonStockMember EHVVF:MedicalAdvisoryBoardAgreementsMember 2025-01-01 2025-12-31 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2025-12-31 0001653606 EHVVF:MedicalAdvisoryBoardAgreementsMember 2024-12-31 0001653606 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001653606 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-12-31 0001653606 EHVVF:AiboticsIncMember 2024-01-01 2024-12-31 0001653606 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-12-31 0001653606 EHVVF:AiboticsIncMember 2025-01-01 2025-12-31 0001653606 us-gaap:WarrantMember 2025-12-31 0001653606 us-gaap:WarrantMember 2023-12-31 0001653606 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001653606 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001653606 us-gaap:WarrantMember 2024-12-31 0001653606 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001653606 2025-01-01 2025-03-31 0001653606 EHVVF:TwoThousandTwentySixEquityIncentivePlanMember us-gaap:SubsequentEventMember EHVVF:AiboticsIncMember 2026-01-01 2026-05-15 0001653606 EHVVF:ConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember EHVVF:AiboticsIncMember 2026-05-15 0001653606 EHVVF:PromissoryNoteMember us-gaap:SubsequentEventMember EHVVF:AiboticsIncMember 2026-05-15 0001653606 EHVVF:PromissoryNoteMember us-gaap:SubsequentEventMember EHVVF:AiboticsIncMember 2026-01-01 2026-05-15 0001653606 us-gaap:SubsequentEventMember EHVVF:AiboticsIncMember 2026-01-01 2026-05-15 0001653606 us-gaap:SubsequentEventMember EHVVF:AiboticsIncMember 2026-05-15 iso4217:USD shares iso4217:USD shares pure iso4217:CAD EHVVF:Integer true FY 0001653606

Unlimited

20-F/A Amendment No. 1 false true 2025-12-31 --12-31 2025 false false 000-56146 EHAVE, INC A6 100 SE 2nd St. Suite 2000 Miami FL 33131 US Benjamin Kaplan 954 233-3511 100 SE 2nd St. Suite 2000 Miami FL 33131 US Common Shares, no par value 1482014555 No No Yes Yes Non-accelerated Filer true false false U.S. GAAP false false To date, the Company has <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zJgm3ShUcHPd">not identified any cybersecurity incidents which have materially affected, or are reasonably likely to materially affect, the Company’s business strategy, results of operations or financial condition. The Company has not implemented any specific policies with respect to monitoring and managing cybersecurity threats. Moreover, the Company is aware of the evolution of cybersecurity risks and is taking proactive steps by keeping up to date our information systems and educating our personnel about these risks. The Company recognizes the importance of developing, implementing, and maintaining cybersecurity measures to safeguard its information systems and protect the confidentiality, integrity, and availability of the data. The Company will be looking to adopt cybersecurity processes, technologies and controls to aid in its efforts to assess, prevent, identify and manage such risks. false 5525 We have audited the accompanying consolidated balance sheets of Ehave, Inc. (“the Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations and other comprehensive loss, changes in stockholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2025, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and 2024 and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. Fruci & Associates II, PLLC Spokane, Washington

791432

833125

14167

805599

833125

2896172

1271898

3701771

2105023

5771101

5073241

807000

864000

120689

224020

1754064

1790597

4695600 2039600

13148454

9991458

13148454

9991458

1482014555

359571047

30315968

29742533

3157789 3157789

-40767900

-38292380

168598

196089

-7125545

-5195969

-2321138

-2690466

-9446683

-7886435

3701771

2105023

2183

1579137

1469044

1175726

667883

543253 366929

3298116

2503856

-3295933

-2503856

416018

414673

44528

169655

-460546

-245018

-3756479

-2748874

-3756479

-2748874

-1280959

-630262

-2475520

-2118612

-27491

48886

-27491

48886

-3783970

-2699988

-0.002

-0.006

1316810694

359571047

29742533

3157789

-36173768

147203

-3126243

-2542021

-5668264

477417 477417

4400

48886

-2118612

-630262

-2748874

359571047

29742533

3157789

-38292380

196089

-5195969

-2690466

-7886435

1000000000 250000 250000 250000

22443508

223435

100000000 100000 100000 100000 363166 363166 225000 225000 50000 50000 1012121 1012121

-27491

-2475520

-1280959

-3756479

1482014555

30315968

3157789

-40767900

168598

-7125545

-2321138

-9446683

-3756479

-2748874

498

1175726

667883

-79591 91248

16973

9350

-35833

2004497

1455145

168000 288000

-264202

-248407

300000

50000

250000

-27491

48886

-41693

-199521

833125

1032646

791432

833125

250000 477417 223435 2800000 363166 225000 50000 968121

44000

<p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zv4WSQMT58cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">1. ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization and General Description of Business EHAVE, Inc. (formerly known as “Behavioral Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011. KetaDash Inc. (Ketadash), a wholly owned subsidiary of Ehave, Inc. (Ehave), provides a platform for medical practitioners to administer healthcare services to patients at home. In order to facilitate the launch of Ketadash, Ehave acquired <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RejuvIVIncMember_zmg9h7kSM3q9" title="Equity method investment ownership percentage">100% of Rejuv IV inc. (Rejuv IV) through a stock purchase agreement on January 8, 2021. Ehave then consolidated Rejuv IV into its Ketadash brand. KetaDash addresses the needs of patients currently suffering from mental illnesses such as depressive disorder, bipolar disorder and post-traumatic stress disorder. KetaDash improves brain wellness and cognitive function with psychedelic medicine administered by a registered nurse in the comfort of your own home with Ketadash’s mobile wellness therapies. Ketadash provides Ketamine treatments, as well as IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. In addition to Ketamine treatments, Ketadash generates revenue by offering its clients and patients IV Drip Detox and Hangover Cures, IV Vitamin Therapy for pain management, Hydration Therapy for Health & Wellness, and IV Therapy for athletic advantage and fitness recovery. Ketadash uses certified nurses, who are always prompt and will arrive on time to administer a patient’s IV drip of choice in the comfort of their home. Ketadash’s products and services have been made public through their website https://ketadash.com/. The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors. Aibotic’s sponsors research and development of the use of psychedelics for the treatment of mental health issues utilizing the technology developed by Ehave. Basis of Presentation and principles of consolidation These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its subsidiary, Aibotics, Inc. (“Aibotics”) of which the Company has a <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AiboticsIncMember_zJ8h8rz5cupa" title="Ownership percentage">65.90% controlling ownership interest. All inter-company accounts and transaction have been eliminated in consolidation. Foreign Currency Translation The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income. Foreign Currency Risk The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints. Segment Reporting The Company adopted ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. The Company operates in one operating segment, and therefore one reportable segment, focused on developing and commercializing AI technology platform solutions. The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM manages the Company’s business activities as a single operating and reportable segment at the consolidated level. Accordingly, the CODM uses consolidated net loss to allocate resources and assess performance. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. Cash and cash equivalents The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments. Software Products and Research and Development Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method. For the years ended December 31, 2025 and 2024, the Company recorded $<span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zceS6m49ZgB7" title="General and administrative expense">10,500 and $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zMhUP8Pw0qMa" title="General and administrative expense">17,784, respectively, as general and administrative expense for software development costs. Advertising Costs The Company expenses advertising costs as incurred. Advertising expense totaled $2,450 and $0 for the years ended December 31, 2025 and 2024, respectively. Property and Equipment Property and equipment is recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight-line method of the estimated useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major improvements are capitalized and depreciated over the remaining useful lives of the assets. During the year ended December 31, 2025 and 2024, the Company had no impairment on fixed assets. The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">Medical equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">5 years</td></tr> </table> As of December 31, 2025 and 2024, property and equipment consisted of the following: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zYjOaRKa7Ae8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z7Ofjl0TCOIl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zEuJZ5rJomq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Medical equipment</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,995</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,995</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz8pC_zaksrYqJh08k" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,995</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,995</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz8pC_zKDj6jqPfUAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less, accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,995</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,995</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz8pC_z9GdKj0lRpCd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equipment, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table> During the years ending December 31, 2025 and 2024, the Company recorded depreciation expense of approximately $0 and $498, respectively. Impairment of Long-lived Assets Management reviews long-lived assets that are held and used for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared with the asset’s carrying amount to determine if there has been an impairment, which is calculated as the difference between the fair value of an asset and its carrying value. Estimates of future undiscounted cash flows are based on expected growth rates for the business, anticipated future economic conditions and estimates of residual values. Fair values take into consideration management’s estimates of risk-adjusted discount rates, which are believed to be consistent with assumptions that marketplace participants would use in their estimates of fair value. There were no impairments of long-lived assets recognized during the years ended December 31, 2025 and 2024. Leases The Company reviews all arrangements for potential leases in accordance with ASC 842, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised. Historically, the Company reimbursed its CEO, Ben Kaplan, for leased office space in the amount of $4,000 per month. However, the lease was no longer active during the year ended December 31, 2025. For the year ending December 31, 2025 and 2024, rent expense was $0 and $48,000. Other than the Company’s reimbursement of its CEO for rent on a month-to-month basis, the Company has not entered into any lease agreements. Income Taxes Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. Net Loss per Common Share, basic The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the year ended December 31, 2025, the Company had outstanding warrants to purchase 28,770,478 common shares and 81,628,267 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. For the year ended December 31, 2024, the Company had outstanding warrants to purchase 28,770,478 common shares and 142,928,343 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. Recent Accounting Pronouncements During the periods ended December 31, 2025 and 2024 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker (“CODM”). ASU 2023-07 does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The Company adopted this guidance on a retrospective basis as of January 1, 2025 and the adoption of this guidance had no material impact on the consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The adoption of ASU 2023-09 did not have a material impact on the Company’s related disclosures.

Organization and General Description of Business EHAVE, Inc. (formerly known as “Behavioral Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011. KetaDash Inc. (Ketadash), a wholly owned subsidiary of Ehave, Inc. (Ehave), provides a platform for medical practitioners to administer healthcare services to patients at home. In order to facilitate the launch of Ketadash, Ehave acquired <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RejuvIVIncMember_zmg9h7kSM3q9" title="Equity method investment ownership percentage">100% of Rejuv IV inc. (Rejuv IV) through a stock purchase agreement on January 8, 2021. Ehave then consolidated Rejuv IV into its Ketadash brand. KetaDash addresses the needs of patients currently suffering from mental illnesses such as depressive disorder, bipolar disorder and post-traumatic stress disorder. KetaDash improves brain wellness and cognitive function with psychedelic medicine administered by a registered nurse in the comfort of your own home with Ketadash’s mobile wellness therapies. Ketadash provides Ketamine treatments, as well as IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. In addition to Ketamine treatments, Ketadash generates revenue by offering its clients and patients IV Drip Detox and Hangover Cures, IV Vitamin Therapy for pain management, Hydration Therapy for Health & Wellness, and IV Therapy for athletic advantage and fitness recovery. Ketadash uses certified nurses, who are always prompt and will arrive on time to administer a patient’s IV drip of choice in the comfort of their home. Ketadash’s products and services have been made public through their website https://ketadash.com/. The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors. Aibotic’s sponsors research and development of the use of psychedelics for the treatment of mental health issues utilizing the technology developed by Ehave.

Basis of Presentation and principles of consolidation These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its subsidiary, Aibotics, Inc. (“Aibotics”) of which the Company has a <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AiboticsIncMember_zJ8h8rz5cupa" title="Ownership percentage">65.90% controlling ownership interest. All inter-company accounts and transaction have been eliminated in consolidation.

0.6590

Foreign Currency Translation The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income.

Foreign Currency Risk The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.

Segment Reporting The Company adopted ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. The Company operates in one operating segment, and therefore one reportable segment, focused on developing and commercializing AI technology platform solutions. The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM manages the Company’s business activities as a single operating and reportable segment at the consolidated level. Accordingly, the CODM uses consolidated net loss to allocate resources and assess performance. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets.

Cash and cash equivalents The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.

Software Products and Research and Development Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method. For the years ended December 31, 2025 and 2024, the Company recorded $<span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zceS6m49ZgB7" title="General and administrative expense">10,500 and $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zMhUP8Pw0qMa" title="General and administrative expense">17,784, respectively, as general and administrative expense for software development costs.

10500

17784

Advertising Costs The Company expenses advertising costs as incurred. Advertising expense totaled $2,450 and $0 for the years ended December 31, 2025 and 2024, respectively.

2450

Property and Equipment Property and equipment is recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight-line method of the estimated useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major improvements are capitalized and depreciated over the remaining useful lives of the assets. During the year ended December 31, 2025 and 2024, the Company had no impairment on fixed assets. The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">Medical equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">5 years</td></tr> </table> As of December 31, 2025 and 2024, property and equipment consisted of the following: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zYjOaRKa7Ae8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z7Ofjl0TCOIl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zEuJZ5rJomq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Medical equipment</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,995</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,995</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz8pC_zaksrYqJh08k" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,995</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,995</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz8pC_zKDj6jqPfUAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less, accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,995</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,995</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz8pC_z9GdKj0lRpCd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equipment, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table> During the years ending December 31, 2025 and 2024, the Company recorded depreciation expense of approximately $0 and $498, respectively.

The assets’ estimated lives used in computing depreciation for property, plant and equipment are as follows: SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">Medical equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">5 years</td></tr> </table>

P5Y

As of December 31, 2025 and 2024, property and equipment consisted of the following: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zYjOaRKa7Ae8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_z7Ofjl0TCOIl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zEuJZ5rJomq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Medical equipment</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,995</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,995</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz8pC_zaksrYqJh08k" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,995</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,995</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz8pC_zKDj6jqPfUAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less, accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,995</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,995</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz8pC_z9GdKj0lRpCd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equipment, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

2995

498

Impairment of Long-lived Assets Management reviews long-lived assets that are held and used for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared with the asset’s carrying amount to determine if there has been an impairment, which is calculated as the difference between the fair value of an asset and its carrying value. Estimates of future undiscounted cash flows are based on expected growth rates for the business, anticipated future economic conditions and estimates of residual values. Fair values take into consideration management’s estimates of risk-adjusted discount rates, which are believed to be consistent with assumptions that marketplace participants would use in their estimates of fair value. There were no impairments of long-lived assets recognized during the years ended December 31, 2025 and 2024.

Leases The Company reviews all arrangements for potential leases in accordance with ASC 842, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised. Historically, the Company reimbursed its CEO, Ben Kaplan, for leased office space in the amount of $4,000 per month. However, the lease was no longer active during the year ended December 31, 2025. For the year ending December 31, 2025 and 2024, rent expense was $0 and $48,000. Other than the Company’s reimbursement of its CEO for rent on a month-to-month basis, the Company has not entered into any lease agreements.

4000

48000

Income Taxes Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.

Net Loss per Common Share, basic The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the year ended December 31, 2025, the Company had outstanding warrants to purchase 28,770,478 common shares and 81,628,267 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. For the year ended December 31, 2024, the Company had outstanding warrants to purchase 28,770,478 common shares and 142,928,343 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.

28770478

81628267

28770478

142928343

Recent Accounting Pronouncements During the periods ended December 31, 2025 and 2024 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker (“CODM”). ASU 2023-07 does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The Company adopted this guidance on a retrospective basis as of January 1, 2025 and the adoption of this guidance had no material impact on the consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The adoption of ASU 2023-09 did not have a material impact on the Company’s related disclosures.

2. GOING CONCERN The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States, which contemplate the continuation of the Company as a going concern. Through December 31, 2025, the Company has incurred an accumulated deficit of $40,767,900, primarily as a result of expenses incurred through a combination of development and commercialization activities related to our products and general and administrative expenses supporting those activities, as well as an operating loss of $3,295,932 for the year ended December 31, 2025. Our total cash balance as of December 31, 2025 was $791,432. At December 31, 2025, we had a working capital deficit of $12,342,855. We anticipate that we will continue to incur losses and negative cash flows from operations, and that such losses will increase over the next several years. As a result of these expected losses and negative cash flows from operations, along with our current cash position, we may not have sufficient resources to fund operations for one year from the date we issued these financial statements. Therefore, there is substantial doubt about our ability to continue as a going concern.

-40767900

-3295932

791432

12342855

3. FAIR VALUE MEASUREMENT ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Other current assets, accounts payable and accrued expenses, and convertible notes are all stated at book value due to the term and nature of such items. The three levels of the fair value hierarchy under ASC 820 are described below: Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data; Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. There were no changes in the fair value hierarchy leveling during the years ended December 31, 2025 and 2024.

4. RELATED PARTY TRANSACTIONS Notes Payable – Related Parties On January 30, 2024, the Company signed an agreement with a major shareholder for a $165,000 note payable. The note accrues interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240130__srt--TitleOfIndividualAxis__custom--MajorShareholderMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MajorShareholderMember_zcn5gVQw5KKf" title="Interest rate">1.75% compounded annually and has a maturity date of January 30, 2025 (Note 6 – Promissory and Convertible Notes). The note had interest expense of $2,880 and $2,658 for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, the Company had recorded accrued interest of $4,090 related to the note within accrued interest on the Consolidated Balance Sheet. Consulting Agreement with the CEO On January 1, 2021, the Company entered into an Executive Consulting Agreement, which superseded the previous consulting agreement, with Benjamin Kaplan to serve as the Company’s CEO for an initial term of <span id="xdx_909_ecustom--EmploymentTerm_c20210101__20210101__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_znt6pgRSJesf" title="Employment term">36 months. As of December 31, 2025, and 2024, the Company has recorded $<span id="xdx_904_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zgeT6iZCRWt3" title="Accrued expense">1,575,948 and $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zXPg5IndjR0j" title="Accrued expense">1,417,548, respectively, as accrued expense in relation to the Executive Consulting Agreement. As of December 31, 2025 and 2024, the Company has accrued balance of $<span id="xdx_90F_ecustom--AccruedCompensationEquity_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zJNB4JpGjrKi" title="Equity payable"><span id="xdx_906_ecustom--AccruedCompensationEquity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zMKCGPjToPH6" title="Equity payable">3,157,789 as equity payable in relation to the Executive Consulting Agreement. During the years ending December 31, 2025, and 2024, the Company has recorded $<span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zAgFJitfXH9" title="General and administrative expenses">408,400 and $<span id="xdx_90B_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zMuZIK5XpoAc" title="General and administrative expenses">408,400 as general and administrative expenses in relation to the executive consulting agreement. During the year ending December 31, 2025, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zRjt49vCrWi8" title="Number of shares issued">1,000,000,000 shares of common stock to settle $<span id="xdx_90B_eus-gaap--PaymentsToEmployees_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_z8EkX8mWZbw2" title="Payments to CEO">250,000 of the balance owed to the CEO in relation to the Executive Consulting Agreement. The Company did not make any cash payments to the CEO for Executive Consulting Agreement during the years ended December 31, 2025 and 2024. On June 24, 2019, the Company entered into an Executive Consulting Agreement (Agreement) with Benjamin Kaplan (BK) to serve as the Company’s CEO for an initial term of <span id="xdx_903_ecustom--EmploymentTerm_c20190623__20190624__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zFlPkqKCdRai" title="Initial term">24 months. In addition to the monthly consulting fee, the Agreement provides for a one month ‘termination fee’ if the Agreement is terminated without cause. On June 29, 2019, the Company and BK amended the Agreement as follows: BK was granted a Warrant to purchase that number of shares of common stock of the Company equal to <span id="xdx_903_ecustom--CommonStockIssuedAndOutstandingPercentage_iI_pid_dp_c20190629__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zPDOfC2TvUik" title="Common stock issued and outstanding percentage">5% of the issued and outstanding common shares, on a fully diluted basis. The Warrant was issued on April 16, 2020, has an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200416__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zClYBJiN2wYk" title="Warrants exercise price">0.01 USD per share and expired on <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200416__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zjKb2T2UFUqb" title="Warrant expiry date">April 16, 2022. During the year ended December 31, 2020, the Company issued <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zEONhOszjrTe" title="Shares issued upon exercise of warrants">3,358,498 vested warrants to Ben Kaplan, the Company’s CEO, in accordance with his employment agreement valued at $<span id="xdx_901_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zBXgiQB02mHd" title="Warrants issued during period, value">720,695 (see Note 7). Upon the closing of a Significant Transaction (defined as the closing of financing for at least $<span id="xdx_90C_eus-gaap--PaymentForContingentConsiderationLiabilityFinancingActivities_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--RangeAxis__srt--MinimumMember_zE4k34AkN6Jh" title="Payment for contingent consideration">500,000 or the closing of an acquisition with a valuation (determined by the value of the consideration paid by the Company) of not less than $<span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--RangeAxis__srt--MinimumMember_zYbkVQYoZK39" title="Payment of consideration for rendered services">1,000,000 USD), BK would be granted a number of shares equal to 5% of the issued and outstanding common shares, on a fully diluted basis including such shares to be issued or that could be issued pursuant to the transaction on the closing date of such Significant Transaction. This stock grant can be earned by BK for each Significant Transaction closed during the term of the Agreement. On January 1, 2021, the Company entered into a new consulting agreement with the CEO for a term of <span id="xdx_901_ecustom--EmploymentTerm_c20210101__20210101__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_z1TSPH0xBRtf" title="Initial term">36 months and will automatically renew for an additional 12 months. Compensation under the January 1, 2021 agreement is as follows: Annual Salary Compensation The Company shall pay the CEO a fee of $<span id="xdx_908_eus-gaap--SalariesWagesAndOfficersCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zR4rslQil387" title="Annual salary compensation">24,000 per month as annual salary compensation. During the years ended December 31, 2025 and 2024, the Company recorded $<span id="xdx_90A_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_ziYFbY2n1MH8" title="General and administrative expense"><span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zqP24MJIpO0i" title="General and administrative expense">288,000 as general and administrative expense for the CEO fee. Bonus The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following EBITDA milestones. For the year ending December 31, 2025, no EBITDA milestones were met and no amounts have been recorded for the bonus milestones. SCHEDULE OF BONUS AND MILESTONES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Bonus (Canadian Dollars)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">EBITDA Milestones (Canadian Dollars)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesOneMember_zVZ3OItnNPzb" style="width: 47%; text-align: right" title="Bonus">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 47%; text-align: right">1st $<span id="xdx_908_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesOneMember_z8z2RSQO6pJ8" title="Revenue recognition milestone method">1,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesTwoMember_zJ2yYrIMYglf" style="text-align: right" title="Bonus">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2nd $<span id="xdx_90F_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesTwoMember_znoibYadWrcd" title="Revenue recognition milestone method">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesThreeMember_zmvKnHV1D6z3" style="text-align: right" title="Bonus">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3rd $<span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesThreeMember_z8aDhMUtYCU7" title="Revenue recognition milestone method">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesFourMember_zsjr662z3y4a" style="text-align: right" title="Bonus">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4th $<span id="xdx_901_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesFourMember_zcrfPGpVwmD8" title="Revenue recognition milestone method">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesFiveMember_zIy89tvQvoS2" style="text-align: right" title="Bonus">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5th $<span id="xdx_903_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesFiveMember_zo1Vo2mlB3O8" title="Revenue recognition milestone method">1,000,000</td><td style="text-align: left"> </td></tr> </table> The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Market Capitalization by maintaining the below market cap for a period of 22 consecutive trading days: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Bonus (Shares)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Market Capitalization Milestone (Canadian Dollars)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember_znOjjUTfxdhl" style="width: 47%; text-align: right" title="Bonus shares">5,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember_zyQ3kwiXDaI3" style="width: 47%; text-align: right" title="Revenue recognition milestone method">20,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember_zaQxuX0AiFEj" style="text-align: right" title="Bonus shares">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember_zxOE5IzRiph6" style="text-align: right" title="Revenue recognition milestone method">40,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember_zxl71bHHk4Dh" style="text-align: right" title="Bonus shares">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember_z50VCNBnRCaa" style="text-align: right" title="Revenue recognition milestone method">60,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember_z1DXWQm5LOUg" style="text-align: right" title="Bonus shares">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember_zSFd0WXB0d0c" style="text-align: right" title="Revenue recognition milestone method">80,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember_znYNpW9SAcce" style="text-align: right" title="Bonus shares">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember_zcmkqAh6DHS3" style="text-align: right" title="Revenue recognition milestone method">100,000,000</td><td style="text-align: left"> </td></tr> </table> Stock Grants – Significant Transactions Upon the Company closing of a Significant Transaction, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_z9CYRBraRZ55" title="Stock grants significant transactions">the CEO shall be granted shares of common stock or new series of preferred shares of the Company that is convertible into common stock equal to 10% of the value of all the consideration, including any stock, cash or debt of such completed transaction. The CEO shall earn this grant for each Significant Transaction closed by the Company. A “Significant Transaction” shall mean a licensing transaction, merger with or acquisition of an operating company in a strategic or synergistic line of business, and a financing or direct or indirect share issuance transaction involving the Company, which as a whole, provides cash flow or equivalent value in excess of $<span id="xdx_90E_ecustom--SignificantTransactionAmount_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zJmbJbXpclTj" title="Cash flow or equivalent value">250,000. For the years ending December 31, 2025 and 2024, the Company accrued $<span id="xdx_902_ecustom--AccruedCompensation_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zfRA3rP9p3Y1" title="Accrued compensation">0 and $<span id="xdx_905_ecustom--AccruedCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zTDIfGzzOsr1" title="Accrued compensation">0 respectively as equity payable. There were no Significant Transaction milestones met as of December 31, 2025 and 2024. Equity Payable to Chief Executive Officer As of December 31, 2025 and 2024, the Company recorded $<span id="xdx_905_ecustom--AccruedCompensationEquity_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zZ02A4Num8Wl" title="Accrued compensation equity">3,157,789 and $<span id="xdx_900_ecustom--AccruedCompensationEquity_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zl4nIGJbCL3i" title="Accrued compensation equity">3,157,789, respectively, as equity payable for Significant Transactions. During the years ended December 31, 2025 and 2024, the Company recorded $0 and $0, respectively. Other Expenses The Company will reimburse the CEO for other expenses of $<span id="xdx_903_eus-gaap--OtherExpenses_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zpsOlAZBeba7" title="Other expenses">3,000 per month. Assistant The Company will reimburse the CEO up to $<span id="xdx_907_ecustom--ReimbursementExpenses_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zxJoISgQDIqh" title="Reimbursement expenses">700 per weeks to hire an assistant. Rent Prior to the year ended December 31, 2025 the Company reimbursed the CEO up to $<span id="xdx_905_eus-gaap--PaymentsForRent_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember_zsomHmCRdgql" title="Rent">4,000 per month to lease office space to be used for Company matters. The Company did not incur any rent expense related to this lease during the year ended December 31, 2025 as the lease was no longer active. Consulting Agreement with CFO On October 1, 2020, the Company entered into a consulting agreement with its CFO, James Cardwell, for an initial term of one year. The agreement was extended for an additional year on its anniversary. Under the terms of the agreement, compensation was set at a minimum of $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JamesCardwellMember_zRCi3LzDvCwl" title="Compensaion paid">1,500 per month. The agreement was terminated as of December 31, 2023, and the Company has not appointed a replacement. As of December 31, 2025 and 2024, the Company had accrued $<span id="xdx_90A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JamesCardwellMember_zuD4oOkAYUVl" title="Accrued expense">0 and $<span id="xdx_903_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JamesCardwellMember_zbJETCeu3zsi" title="Accrued expense">0, respectively, in connection with this agreement, which is included in accrued expenses. Consulting Agreement with Chief Technology Officer On January 1, 2020, the Company entered into an executive employment agreement with the Chief Technology Officer. The Company agreed to pay the executive $<span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20200101__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefTechonologyOfficerMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementMember_z6kyPIao4796" title="Annual service">120,000 annually for services rendered. As of December 31, 2025 the executive employment agreement was no longer active. As of December 31, 2025 and 2024, the Company had accrued expenses of $<span id="xdx_90E_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefTechonologyOfficerMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementMember_zskuvDDOsfC5" title="Accrued expenses"><span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefTechonologyOfficerMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementMember_znjdbGw3Z6x9" title="Accrued expenses">209,597 related to this agreement.

165000

0.0175

2025-01-30

2880

2658

4090

P36M

1575948

1417548

3157789 3157789

408400

1000000000

250000

P24M 0.05

0.01

2022-04-16

3358498

720695

500000

1000000

P36M

24000

288000

The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following EBITDA milestones. For the year ending December 31, 2025, no EBITDA milestones were met and no amounts have been recorded for the bonus milestones. SCHEDULE OF BONUS AND MILESTONES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Bonus (Canadian Dollars)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">EBITDA Milestones (Canadian Dollars)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesOneMember_zVZ3OItnNPzb" style="width: 47%; text-align: right" title="Bonus">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 47%; text-align: right">1st $<span id="xdx_908_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesOneMember_z8z2RSQO6pJ8" title="Revenue recognition milestone method">1,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesTwoMember_zJ2yYrIMYglf" style="text-align: right" title="Bonus">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2nd $<span id="xdx_90F_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesTwoMember_znoibYadWrcd" title="Revenue recognition milestone method">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesThreeMember_zmvKnHV1D6z3" style="text-align: right" title="Bonus">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3rd $<span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesThreeMember_z8aDhMUtYCU7" title="Revenue recognition milestone method">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesFourMember_zsjr662z3y4a" style="text-align: right" title="Bonus">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4th $<span id="xdx_901_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesFourMember_zcrfPGpVwmD8" title="Revenue recognition milestone method">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesFiveMember_zIy89tvQvoS2" style="text-align: right" title="Bonus">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5th $<span id="xdx_903_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--EBITDAMilestonesFiveMember_zo1Vo2mlB3O8" title="Revenue recognition milestone method">1,000,000</td><td style="text-align: left"> </td></tr> </table> The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Market Capitalization by maintaining the below market cap for a period of 22 consecutive trading days: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Bonus (Shares)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Market Capitalization Milestone (Canadian Dollars)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember_znOjjUTfxdhl" style="width: 47%; text-align: right" title="Bonus shares">5,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember_zyQ3kwiXDaI3" style="width: 47%; text-align: right" title="Revenue recognition milestone method">20,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember_zaQxuX0AiFEj" style="text-align: right" title="Bonus shares">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember_zxOE5IzRiph6" style="text-align: right" title="Revenue recognition milestone method">40,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember_zxl71bHHk4Dh" style="text-align: right" title="Bonus shares">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember_z50VCNBnRCaa" style="text-align: right" title="Revenue recognition milestone method">60,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember_z1DXWQm5LOUg" style="text-align: right" title="Bonus shares">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember_zSFd0WXB0d0c" style="text-align: right" title="Revenue recognition milestone method">80,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesIssued_iI_pid_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember_znYNpW9SAcce" style="text-align: right" title="Bonus shares">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenjaminKaplanMember__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember_zcmkqAh6DHS3" style="text-align: right" title="Revenue recognition milestone method">100,000,000</td><td style="text-align: left"> </td></tr> </table>

100000

1,000,000

100000

1,000,000

100000

1,000,000

100000

1,000,000

100000

1,000,000

5000000

20,000,000

5000000

40,000,000

5000000

60,000,000

5000000

80,000,000

5000000

100,000,000

the CEO shall be granted shares of common stock or new series of preferred shares of the Company that is convertible into common stock equal to 10% of the value of all the consideration, including any stock, cash or debt of such completed transaction.

250000 0 0 3157789 3157789 0 0

3000

700

4000

1500

120000

209597

5. INTANGIBLE ASSETS, NET On November 28, 2024, Aibotics entered into an asset sale and purchase agreement with Philon Labs, LLC. (the “seller” or “Philon Labs”) for consideration of approximately $2,000,000 in exchange for intellectual property intangible assets. The purpose of the assets purchase was to begin Aibotic’s transition to a growth-oriented company that applies advanced engineering and design techniques to new products. The entire purchase consideration was allocated as fair value to the intellectual property acquired from the seller. The $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zxJbZqybjfLd" title="Number of shares issued">2,000,000 is to be paid through the issuance of a new series of Aibotics Preferred Stock. As of December 31, 2025, the consideration has not been issued to the seller and is recorded as shares to be issued on the consolidated balance sheet. The Company has analyzed the shares to be issued balance and determined that they are liabilities in accordance with ASC 480 – Distinguishing Liabilities from Equity. For the year ended December 31, 2024, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--AiboticsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHpMK9qqzjc1" title="Number of shares issued">200,000 shares of Aibotics Series B Preferred Stock to the seller as satisfaction of the intangible assets’ consideration in the amount of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--AiboticsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zXl4gwsf484k" title="Number of shares issued, value">4,400. No shares were issued during the year ended December 31, 2025. On May 23, 2025, the Company entered into an Asset Purchase Agreement (the “Klizos APA”) with Klizos Ventures, Inc (“Klizos”). Pursuant to the Klizos APA the Company acquired certain intellectual property intangible assets related to Klizos’s AIHeadhunter platform. The Company agreed to issue Klizos $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250523__20250523__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z4Zb4NbDwk94" title="Number of shares issued, value">2,800,000 of consideration, composed of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250523__20250523__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zidndVBuAnPj" title="Number of shares issued">100,000,000 shares of common stock and $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250523__20250523__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zY7UlnBAg8bg" title="Number of shares issued, value">2,700,000 of Preferred Stock. As of December 31, 2025 the common stock has been issued but the Preferred Stock remains unissued, and is therefore recorded shares to be issued on the consolidated balance sheet. The Company has analyzed the shares to be issued balance and determined that they are liabilities in accordance with ASC 480 – Distinguishing Liabilities from Equity. The shares to be issued liability due to Klizos was recorded at a value of $2,700,000. The Klizos APA also features an earn-out provision that stipulates Klizos is to receive up to $7,000,000 of additional shares of Preferred Stock as the following milestones are met: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Milestone 1: If the platform is fully launched and has at least ten paying customers Klizos will receive $250,000 of Preferred Stock</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Milestone 2: If the platform reaches $1,000,000 in cumulative gross revenue Klizos will receive $500,000 of Preferred Stock</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Milestone 3: If the platform reaches $3,000,000 in cumulative gross revenue Klizos will receive $1,250,000 of Preferred Stock</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Milestone 4: If the platform reaches $5,000,000 in cumulative gross revenue Klizos will receive $1,750,000 of Preferred Stock</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Milestone 5: If the platform reaches $7,500,000 in cumulative gross revenue Klizos will receive $3,250,000 of Preferred Stock</td></tr></table> The intellectual property intangible assets are being amortized over their estimated useful lives of 3 years. Intangible assets as of December 31, 2025 and 2024, are as follows: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231_zDAtU6q7h0l7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20241213_zGx7n52P6sAb" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANz1ZK_zSHUPWwImbZf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Intellectual property</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,800,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANz1ZK_zrZMlryMuweg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,903,828</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(728,102</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz1ZK_zoUPMrJ3Toel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,896,172</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,271,898</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Amortization expense from intangible assets was $1,175,726 and $667,883 for the year ended December 31, 2025 and 2024, respectively. <p id="xdx_89A_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zd089p5TtR0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Future amortization expense from intangible assets as of December 31, 2025, were as follows: SCHEDULE OF FUTURE AMORTIZATION EXPENSE FROM INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20251231_ziLP2VrhBBhh" style="font-weight: bold; text-align: center">For the Year Ended,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzU2c_zxVzjtsnI2mc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,537,048</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzU2c_zjvjZaTfrLO4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">932,482</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzU2c_zoj3bZinCsQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">426,642</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseYearThereafter_iI_maFLIANzU2c_zGkwshtUwXCk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzU2c_ziDeavend0de" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total remaining amortization expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,896,172</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2000000

200000

4400

2800000

100000000

2700000

2700000 7000000 If the platform is fully launched and has at least ten paying customers Klizos will receive $250,000 of Preferred Stock If the platform reaches $1,000,000 in cumulative gross revenue Klizos will receive $500,000 of Preferred Stock If the platform reaches $3,000,000 in cumulative gross revenue Klizos will receive $1,250,000 of Preferred Stock If the platform reaches $5,000,000 in cumulative gross revenue Klizos will receive $1,750,000 of Preferred Stock If the platform reaches $7,500,000 in cumulative gross revenue Klizos will receive $3,250,000 of Preferred Stock

P3Y

Intangible assets as of December 31, 2025 and 2024, are as follows: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231_zDAtU6q7h0l7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20241213_zGx7n52P6sAb" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANz1ZK_zSHUPWwImbZf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Intellectual property</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,800,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANz1ZK_zrZMlryMuweg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,903,828</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(728,102</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz1ZK_zoUPMrJ3Toel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,896,172</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,271,898</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4800000

2000000

1903828

728102

2896172

1271898

1175726

667883

<p id="xdx_89A_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zd089p5TtR0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Future amortization expense from intangible assets as of December 31, 2025, were as follows: SCHEDULE OF FUTURE AMORTIZATION EXPENSE FROM INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20251231_ziLP2VrhBBhh" style="font-weight: bold; text-align: center">For the Year Ended,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzU2c_zxVzjtsnI2mc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,537,048</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzU2c_zjvjZaTfrLO4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">932,482</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzU2c_zoj3bZinCsQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">426,642</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseYearThereafter_iI_maFLIANzU2c_zGkwshtUwXCk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzU2c_ziDeavend0de" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total remaining amortization expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,896,172</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1537048

932482

426642

2896172

6. PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES Convertible Notes On May 6, 2025, the Company issued a lender a convertible note payable with principal of $275,000 and an original issue discount of $25,000. The note matures after 24 months and has an effective interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zo3Vjw0wF2d9" title="Original issue discount rate">10%. As of December 31, 2025, the Company had an outstanding principal amount of $258,185 due to this convertible note payable. As of December 31, 2025 and 2024, the Company has outstanding Convertible Promissory Notes that were issued prior to December 31, 2024 to various holders in an aggregate amount of $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__srt--TitleOfIndividualAxis__custom--VariousHoldersMember_zDza2NU58hua" title="Convertible notes">1,607,902 and $<span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__srt--TitleOfIndividualAxis__custom--VariousHoldersMember_zAghQckHU0V3" title="Convertible notes">2,014,617, respectively. In aggregate, as of December 31, 2025 the principal amount includes an original issue discount (an “OID”) of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zpU71oTJZ9F1" title="Original issue discount rate">10%. All notes are due to mature 18 months from their respective effective date and mature beginning on May 25, 2021 through August 11, 2022. As of December 31, 2025, the outstanding Convertible Promissory Notes were in default. During the years ended December 31, 2025 and 2024, the Company issued 22,443,508 shares of common stock upon conversion of the Notes and accrued interest. Promissory Note On September 12, 2025 the Company issued a promissory note with a principal balance of $58,823 and an original issue discount of $8,823, resulting in cash proceeds of $50,000. The promissory note bears interest at a rate of 12% per annum and matures on January 2, 2026. During the year ended December 31, 2025, the Company made principal repayments of $50,000 towards the promissory note. As of December 31, 2025 the Company had an outstanding principal amount of $8,666 due to the promissory note. The following table summarizes the Notes activity during the years ended December 31, 2025 and 2024: SCHEDULE OF NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">As of</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31,2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Convertible promissory notes, balance at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ConvertibleNotesPayable_iS_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zZZIdvRsb3qj" style="width: 16%; text-align: right" title="Convertible promissory notes, balance">2,005,267</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issuances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zUaIUKklr4S2" style="text-align: right" title="Issuances">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ConversionsOfNotesPayable_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zKOmL1x42Brc" style="text-align: right" title="Conversions">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--DebtInstrumentDiscount_iN_di_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zmvgxtZy0y9l" style="text-align: right" title="Debt discount">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zDtvY90WMp59" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization of debt discount">9,350</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible promissory notes, balance at December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConvertibleNotesPayable_iS_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z48igXAB4JP1" style="text-align: right" title="Convertible promissory notes, balance">2,014,617</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Additions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ConvertiblePromissoryNoteAdditions_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zqYFr8Ybt7ma" style="text-align: right" title="Conversions">333,824</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ConvertibleDebtpaymentsOfShortTermDebt_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zQUA2if0h9B5" style="text-align: right" title="Conversions">(50,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ConversionsOfNotesPayable_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zvIz8J6dS3Ti" style="text-align: right" title="Conversions">(406,837</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt discount (reversal)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--DebtInstrumentDiscount_iN_di_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zGAMWGWrVXW" style="text-align: right" title="Debt discount">(33,824</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z0mWdV2iVLua" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization of debt discount">16,973</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible promissory notes, balance at December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_iE_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z1JXdzRmbnbj" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible promissory notes, balance">1,874,753</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> As of December 31, 2025 and 2024, the Company recorded amortization of debt discount totaling $16,973 and $9,350, respectively, which is included in interest expense on the consolidated statement of operations.

275000

25000

P24M

0.10

258185

1607902

2014617

0.10

May 25, 2021 through August 11, 2022

22443508

58823

8823

50000

0.12

50000

8666

The following table summarizes the Notes activity during the years ended December 31, 2025 and 2024: SCHEDULE OF NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">As of</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31,2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Convertible promissory notes, balance at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ConvertibleNotesPayable_iS_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zZZIdvRsb3qj" style="width: 16%; text-align: right" title="Convertible promissory notes, balance">2,005,267</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issuances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zUaIUKklr4S2" style="text-align: right" title="Issuances">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ConversionsOfNotesPayable_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zKOmL1x42Brc" style="text-align: right" title="Conversions">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--DebtInstrumentDiscount_iN_di_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zmvgxtZy0y9l" style="text-align: right" title="Debt discount">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zDtvY90WMp59" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization of debt discount">9,350</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible promissory notes, balance at December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConvertibleNotesPayable_iS_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z48igXAB4JP1" style="text-align: right" title="Convertible promissory notes, balance">2,014,617</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Additions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ConvertiblePromissoryNoteAdditions_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zqYFr8Ybt7ma" style="text-align: right" title="Conversions">333,824</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ConvertibleDebtpaymentsOfShortTermDebt_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zQUA2if0h9B5" style="text-align: right" title="Conversions">(50,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ConversionsOfNotesPayable_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zvIz8J6dS3Ti" style="text-align: right" title="Conversions">(406,837</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt discount (reversal)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--DebtInstrumentDiscount_iN_di_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zGAMWGWrVXW" style="text-align: right" title="Debt discount">(33,824</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z0mWdV2iVLua" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization of debt discount">16,973</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible promissory notes, balance at December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_iE_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z1JXdzRmbnbj" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible promissory notes, balance">1,874,753</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

2005267

9350

2014617

333824 -50000 -406837 33824

16973

1874753

16973

9350

7. COMMITMENTS AND CONTINGENCIES Collaboration Agreement The Company entered into a collaboration agreement with a hospital located in Canada. As of December 31, 2025 and 2024, the Company recorded $20,000 for the annual royalty payable accrued under the terms of the collaboration agreement. Agreements On November 16, 2021, the Company entered into a consulting agreement for a term of three years to advise the Company and its Ketadash Subsidiary in establishing services to be provided in California. <span id="xdx_900_ecustom--ConsultingPaymentsPercentageDescription_c20211115__20211116__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zKRgnoKwpZX7" title="Consulting payments percentage description">The Company will pay the consultant a percentage of gross profits as follows: (i) 10% of gross profits up to $1,000,000, (ii) 7.5% of gross profits from $1,000,001 to $5,000,000, and (iii) 5% for gross profits exceeding $5,000,001. As of December 31, 2025 and the date of this filing, no amounts have been earned under this contract. Medical Advisory Board Agreements During the period ended December 31, 2020, the Company entered into medical advisory board agreements with four members for a term of one year each. As consideration for the services to be rendered, the Company agreed to pay $<span id="xdx_90E_eus-gaap--PaymentsToSuppliers_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember_zhGB9Wn9X1h8" title="Cash consideration for services to be rendered">45,000 in cash and $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDs8jGEmc1Eg" title="Stock consideration for services to be rendered">155,000 worth of stock in common stock. As of December 31, 2025 and 2024, the Company has accrued $120,001 in relation to these agreements.

20000

P3Y The Company will pay the consultant a percentage of gross profits as follows: (i) 10% of gross profits up to $1,000,000, (ii) 7.5% of gross profits from $1,000,001 to $5,000,000, and (iii) 5% for gross profits exceeding $5,000,001. P1Y

45000

155000

120001

8. STOCKHOLDERS’ EQUITY (DEFICIT) Common Stock During the year ended December 31, 2025, the Company issued <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfAccountsPayableAndAccruedExpenses_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvvRatejHFb5" title="Common stock shares in settlement of accounts payable and accrued expenses">1,000,000,000 shares of common stock in settlement of accounts payable and accrued expenses of $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfAccountsPayableAndAccruedExpenses_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4tf5IN1XAU7" title="Common stock shares in settlement of accounts payable and accrued expenses">250,000. During the year ended December 31, 2025, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBj052TK2G75" title="Common stock shares in settlement of accounts payable and accrued expenses">22,443,508 shares of common stock upon conversion of convertible notes payable and accrued interest of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZStfQoGXGTa" title="Common stock shares in settlement of accounts payable and accrued expenses">223,435. Series A Preferred Stock During the year ended December 31, 2025, the Board of Directors of the Company designated 2,700,000 shares of preferred stock as Series A Preferred Stock. As of December 31, 2025, and 2024 the Company had <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zqlmdLIxkRxg" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzPeSBinDNZ6" title="Preferred stock, shares outstanding">no shares of Series A Preferred Stock issued and outstanding. Additionally, at December 31, 2025, and 2024, the Company had 2,700,000 and 0 shares of Series A Preferred Stock authorized. The Series A Preferred Stock does not have a nominal or par value and has a stated value of $1 per share. The Series A Preferred Stock does not have voting rights and holders of the Series A Preferred Stock are not entitled to receive dividends that are declared or paid to holders of common stock or any other class of the Company’s stock. Upon the occurrence of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary (a “Liquidation”), each holder of Series A Preferred Stock then outstanding shall be entitled to receive, after payment shall be made in respect of any other series of preferred stock then in existence that is outstanding and senior to the Series A Preferred Stock, and before any payment shall be made in respect of the Common Stock, or other series of preferred stock then in existence that is outstanding and junior to the Series A Convertible Preferred Stock upon liquidation, an amount per share of Series A Convertible Preferred Stock up to the stated value of the Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holder into shares of common stock equal to the stated value divided by the conversion price. The conversion price is equal to the VWAP of the Company’s common stock price over the ten (10) trading days preceding, but not including, the conversion date. The Series A Preferred Stock may not be converted into common stock if such a conversion would result in the holder of the Series A Preferred Stock holding an excess of 4.99% of the Company’s common stock outstanding immediately after giving effect to the conversion. The conversion price is subject to standard adjustments for the effects of stock dividends and stock splits. Share Consideration for Acquisition of Intangible Assets During the year ended December 31, 2025, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjWLGfKQXqzf" title="Share consideration for acquisition of intangible assets">100,000,000 shares of common stock, and agreed to issue $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zE20qi7rPC4a" title="Consideration for acquisition of intangible assets">2,700,000 of Series A Preferred Stock for intangible assets of $2,800,000. As of December 31, 2025 the shares of Series A Preferred Stock remained unissued and therefore were recorded as a shares to be issued liability of $2,700,000. See note 5 for more information. Non-Controlling Interest in Aibotics During the year ended December 31, 2024, the Company issued <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfAccountsPayableAndAccruedExpenses_pid_c20240101__20241231__dei--LegalEntityAxis__custom--AiboticsIncMember_zZn3bhIj0zfd" title="Common stock shares in settlement of accounts payable and accrued expenses">477,417 shares of Aibotics common stock to settle $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfAccountsPayableAndAccruedExpenses_pid_c20240101__20241231__dei--LegalEntityAxis__custom--AiboticsIncMember_zGndFYvlZvrg" title="Common stock shares in settlement of accounts payable and accrued expenses">477,417 of accrued expenses. During the year ended December 31, 2024, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDDWJ5XDTwzd" title="Stock issued during period shares issued for services">200,000 shares of Aibotics Series B Preferred Stock to the seller as satisfaction of the intangible assets’ consideration in the amount of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z3exd3J3H26" title="Stock issued during period value issued for services">4,400. During the year ended December 31, 2025 the Company issued <span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfAccountsPayableAndAccruedExpenses_pid_c20250101__20251231__dei--LegalEntityAxis__custom--AiboticsIncMember_zfeZr8wzCn21" title="Common stock shares in settlement of accounts payable and accrued expenses">58,234,996 shares of Aibotics common stock to settle $<span id="xdx_906_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfAccountsPayableAndAccruedExpenses_pid_c20250101__20251231__dei--LegalEntityAxis__custom--AiboticsIncMember_zAsrm9VWtA6j" title="Common stock shares in settlement of accounts payable and accrued expenses">363,166 of accounts payable and accrued expenses. During the year ended December 31, 2025 the Company issued <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedInSettlementOfRelatedPartyAccruedExpenses_pid_c20250101__20251231__dei--LegalEntityAxis__custom--AiboticsIncMember_zgCJC9Z2j9y8" title="Common stock shares in settlement of related party accrued expenses">75,000,000 shares of Aibotics common stock to settle $<span id="xdx_908_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedInSettlementOfRelatedPartyAccruedExpenses_c20250101__20251231__dei--LegalEntityAxis__custom--AiboticsIncMember_zZEcFgBUIbWd" title="Common stock in settlement of related party accrued expenses">225,000 of related party accrued expenses. During the year ended December 31, 2025 the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20251231__dei--LegalEntityAxis__custom--AiboticsIncMember_ztdOYCoRupYj" title="Common stock in exchange for cash proceeds, shares">16,666,667 shares of Aibotics common stock in exchange for cash proceeds of $50,000. During the year ended December 31, 2025, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20250101__20251231__dei--LegalEntityAxis__custom--AiboticsIncMember_zA8YJE4ag7ed" title="Common stock for cash and settlement of accrued interest, net of issuance costs, shares">297,002,793 shares of Aibotics common stock for cash and settlement of accrued interest, net of issuance costs in the amount of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueOther_c20250101__20251231__dei--LegalEntityAxis__custom--AiboticsIncMember_z6FcCbtC1OG1" title="Common stock for cash and settlement of accrued interest, net of issuance costs">1,012,121.

1000000000 250000

22443508

223435

2700000

100000000

2700000

2800000

2700000 477417 477417

200000

4400

58234996 363166 75000000 225000

16666667

50000

297002793

1012121

9. STOCK BASED COMPENSATION During the year ending December 31, 2025 and 2024, the Company had no stock-based compensation. Warrants Issued The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2025 and 2024. SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Underlying Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Term (Years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Warrant outstanding at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxAj850tz2e" style="width: 14%; text-align: right" title="Underlying Shares, Warrants outstanding Beginning balance">29,320,478</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAo1OByprOL9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Beginning balance">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMlfdAZJBkAi" title="Weighted Average Term (Years)">2.52</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeuqkLkSXzld" style="text-align: right" title="Underlying Shares, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zanY1MRwMjdb" style="text-align: right" title="Underlying Shares, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9WGaXIdUkDa" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying Shares, Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrant outstanding at December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKY9vowuDC86" style="text-align: right" title="Underlying Shares, Warrants outstanding Beginning balance">29,320,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zhxmg5Ygkvy9" style="text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Beginning balance">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPaexRDFVqmf" title="Weighted Average Term (Years)">1.51</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQBmQSeKawqh" style="text-align: right" title="Underlying Shares, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPvb5wTBYCo8" style="text-align: right" title="Underlying Shares, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPKi81p5WECi" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying Shares, Forfeited">(3,358,498</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><p id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePriceForfeited_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3LhGRD6SfM7" style="margin: 0" title="Weighted Average Exercise Price, Warrants outstanding Forfeited">0.01</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrant outstanding at December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCLJTkH8SY13" style="text-align: right" title="Underlying Shares, Warrants outstanding Ending balance">25,961,980</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlUAniRAChS1" style="text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Ending balance">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z108gLoglLQ8" title="Weighted Average Term (Years)">0.62</td><td style="text-align: left"> </td></tr> </table> The intrinsic value of warrants outstanding as of December 31, 2025 was $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingIntrinsicValue_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2UPqWGLaoce" title="Intrinsic value of warrants outstanding">0.

The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2025 and 2024. SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Underlying Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Term (Years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Warrant outstanding at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxAj850tz2e" style="width: 14%; text-align: right" title="Underlying Shares, Warrants outstanding Beginning balance">29,320,478</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAo1OByprOL9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Beginning balance">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMlfdAZJBkAi" title="Weighted Average Term (Years)">2.52</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeuqkLkSXzld" style="text-align: right" title="Underlying Shares, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zanY1MRwMjdb" style="text-align: right" title="Underlying Shares, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9WGaXIdUkDa" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying Shares, Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrant outstanding at December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKY9vowuDC86" style="text-align: right" title="Underlying Shares, Warrants outstanding Beginning balance">29,320,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zhxmg5Ygkvy9" style="text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Beginning balance">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPaexRDFVqmf" title="Weighted Average Term (Years)">1.51</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQBmQSeKawqh" style="text-align: right" title="Underlying Shares, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPvb5wTBYCo8" style="text-align: right" title="Underlying Shares, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPKi81p5WECi" style="border-bottom: Black 1pt solid; text-align: right" title="Underlying Shares, Forfeited">(3,358,498</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><p id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePriceForfeited_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3LhGRD6SfM7" style="margin: 0" title="Weighted Average Exercise Price, Warrants outstanding Forfeited">0.01</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrant outstanding at December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCLJTkH8SY13" style="text-align: right" title="Underlying Shares, Warrants outstanding Ending balance">25,961,980</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlUAniRAChS1" style="text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Ending balance">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z108gLoglLQ8" title="Weighted Average Term (Years)">0.62</td><td style="text-align: left"> </td></tr> </table>

29320478

0.01 P2Y6M7D

29320478

0.01 P1Y6M3D

3358498

0.01

25961980

0.01 P0Y7M13D 0

10. INCOME TAXES The Company adopted Accounting Standards Update (ASU) 2023-09, “Improvements to Income Tax Disclosures,” on a retrospective basis within its annual reporting for the year ended December 31, 2025. The adoption of ASU 2023-09 resulted in enhanced disclosures related to the effective tax-rate reconciliation, including additional disaggregation requirements prescribed by the standard. For further details, see Note 1, Organization and Summary of Significant Accounting Policies. The Company computes income taxes using the asset and liability approach. Due to the uncertainty as to the utilization of net operating loss carryforwards, a valuation allowance has been made to the extent of any tax benefit that net operating losses may generate. No provision for income tax has been recorded for the years ended December 31, 2025 and December 31, 2024 due to the Company’s operating losses. As of December 31, 2025, the Company has a net operating loss for tax purposes of CAD $22,393,864 (2024 – CAD $20,303,616) that can be carried forward over 20 years. Deferred Income Taxes Deferred income taxes primarily represent the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. The components of the Company’s deferred taxes are as follows: SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251231_z3i2oQhTIAK8" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zrPauaGhzcs7" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets (liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_maDTAGzYYT_zNfg2H9ZuC5h" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Canada net operating loss carryforwards</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,253,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,928,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGzYYT_zeWp6DS0aWmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">United States net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">965,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">612,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxFixedAssets_iI_maDTAGzYYT_z3YnpZAm9W6i" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Fixed assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: right">58,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: right">58,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DeferredTaxIntangibles_iI_maDTAGzYYT_zR5tsp1deTA9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">356,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">220,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzYYT_ztJYXADpqtxj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">303,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">256,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_mtDTAGzYYT_maDTANzPvO_z4bEr5zVGmp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax asset, ending</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,935,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,074,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzPvO_zGqXD61sLhfa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,935,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,074,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iI_mtDTANzPvO_zaQL4gs8z8Sh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> The reconciliation between income taxes at the Canadian federal rate of 15% and the amount recorded in the accompanying consolidated financial statements is as follows: SCHEDULE OF RECONCILIATION BETWEEN INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49F_20250101__20251231_zHlvx7CchcE5" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49B_20240101__20241231_zCYjh4VWxp9k" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzKjT_z0tU5KCfy439" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left">Canadian Federal statutory tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(556,793</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">15.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(437,780</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">15.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzKjT_z8njbsrC4UHb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Provincial income tax, net of federal income tax effect (1)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maABC01_c20250101__20251231_fKDEp_z0dBawYo0yob" title="Provincial income tax, net of federal income tax effect, percentage">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maABC01_c20240101__20241231_fKDEp_zU8jAExIJXf9" title="Provincial income tax, net of federal income tax effect, percentage">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign tax effects</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzKjT_zlDqhThExh67" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">United States</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(224,793</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(221,265</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.58</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBzKjT_zktNxMGhITZf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effects of changes in tax laws or rates enacted in the current period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">70,886</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_maABC01_c20250101__20251231_zBc8K6e6cZU1" title="Effects of changes in tax laws or rates enacted in the current period, percentage">(1.91</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53,504</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_maABC01_c20240101__20241231_zxhX8jPrX6Oe" title="Effects of changes in tax laws or rates enacted in the current period, percentage">(1.83</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Nontaxable or nondeductible items</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzKjT_zuPnCrxg3O8e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Other permanent items</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,281</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.41</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,223</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzKjT_z7m4ryaRRwre" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">720,069</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maABC01_c20250101__20251231_znNPE9PgW8ha" title="Change in valuation allowance, percentage">(19.40</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">774,052</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maABC01_c20240101__20241231_zkhe7jJaCyNf" title="Change in valuation allowance, percentage">(26.52</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzKjT_zLrYAppMAW8j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Prior period adjustment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(171,734</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.88</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzKjT_zMkKTkGqFuG6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,649</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.66</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_mtITEBzKjT_zOUHRNT0RSK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Income Taxes Provision (Benefit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"></td><td style="text-align: justify">primarily from the province of Ontario</td> </tr></table> The Company paid no income taxes during the years ended December 31, 2025 and 2024 for federal, provincial, or foreign jurisdictions.

22393864

20303616

carried forward over 20 years

SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251231_z3i2oQhTIAK8" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zrPauaGhzcs7" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets (liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_maDTAGzYYT_zNfg2H9ZuC5h" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Canada net operating loss carryforwards</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,253,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,928,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGzYYT_zeWp6DS0aWmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">United States net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">965,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">612,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxFixedAssets_iI_maDTAGzYYT_z3YnpZAm9W6i" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Fixed assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: right">58,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: right">58,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DeferredTaxIntangibles_iI_maDTAGzYYT_zR5tsp1deTA9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">356,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">220,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzYYT_ztJYXADpqtxj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">303,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">256,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_mtDTAGzYYT_maDTANzPvO_z4bEr5zVGmp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax asset, ending</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,935,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,074,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzPvO_zGqXD61sLhfa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,935,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,074,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iI_mtDTANzPvO_zaQL4gs8z8Sh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

4253000

3928000

965000

612000

58000 58000 356000 220000

303000

256000

5935000

5074000

5935000

5074000

The reconciliation between income taxes at the Canadian federal rate of 15% and the amount recorded in the accompanying consolidated financial statements is as follows: SCHEDULE OF RECONCILIATION BETWEEN INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49F_20250101__20251231_zHlvx7CchcE5" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49B_20240101__20241231_zCYjh4VWxp9k" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzKjT_z0tU5KCfy439" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left">Canadian Federal statutory tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(556,793</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">15.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(437,780</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">15.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzKjT_z8njbsrC4UHb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Provincial income tax, net of federal income tax effect (1)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maABC01_c20250101__20251231_fKDEp_z0dBawYo0yob" title="Provincial income tax, net of federal income tax effect, percentage">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maABC01_c20240101__20241231_fKDEp_zU8jAExIJXf9" title="Provincial income tax, net of federal income tax effect, percentage">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign tax effects</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzKjT_zlDqhThExh67" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">United States</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(224,793</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(221,265</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.58</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBzKjT_zktNxMGhITZf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effects of changes in tax laws or rates enacted in the current period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">70,886</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_maABC01_c20250101__20251231_zBc8K6e6cZU1" title="Effects of changes in tax laws or rates enacted in the current period, percentage">(1.91</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53,504</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_maABC01_c20240101__20241231_zxhX8jPrX6Oe" title="Effects of changes in tax laws or rates enacted in the current period, percentage">(1.83</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Nontaxable or nondeductible items</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzKjT_zuPnCrxg3O8e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Other permanent items</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,281</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.41</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,223</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzKjT_z7m4ryaRRwre" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">720,069</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maABC01_c20250101__20251231_znNPE9PgW8ha" title="Change in valuation allowance, percentage">(19.40</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">774,052</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maABC01_c20240101__20241231_zkhe7jJaCyNf" title="Change in valuation allowance, percentage">(26.52</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzKjT_zLrYAppMAW8j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Prior period adjustment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(171,734</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.88</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzKjT_zMkKTkGqFuG6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,649</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.66</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_mtITEBzKjT_zOUHRNT0RSK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Income Taxes Provision (Benefit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"></td><td style="text-align: justify">primarily from the province of Ontario</td> </tr></table>

0.15

-556793

0.1500

-437780

0.1500

0.0000

-224793

0.0606

-221265

0.0758

70886

-0.0191

53504

-0.0183

15281

-0.0041

3223

-0.0011

720069

-0.1940

774052

-0.2652

0.0000

-171734

0.0588

-24649

0.0066

0.0000

11. SEGMENT REPORTING The Company operates in one operating segment, and therefore one reportable segment, focused on developing and commercializing AI technology platform solutions. The accounting policies for the Company’s single operating segment are the same as those described in the summary of significant accounting policies. The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM manages the Company’s business activities as a single operating and reportable segment at the consolidated level. Accordingly, our CODM uses consolidated net loss to allocate resources, and assess performance. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets.

12. SUBSEQUENT EVENTS The Company has evaluated subsequent events from December 31, 2025 the issuance date of these financial statements, and there are no events requiring disclosure other than those described below: Subsequent to December 31, 2025, the Aibiotics Board of Directors approved, by unanimous written consent, the adoption of the Aibotics Inc. 2026 Equity Incentive Plan (the “2026 Plan”), subject to stockholder approval. The 2026 Plan is intended to provide equity-based incentives to employees, directors, consultants, and other service providers and permits the issuance of various types of awards, including stock options, restricted stock, restricted stock units, stock appreciation rights, and other equity-based awards. The 2026 Plan is intended to provide equity-based incentives to employees, directors, consultants, and other service providers and permits the issuance of various types of awards, including stock options, restricted stock, restricted stock units, stock appreciation rights, and other equity-based awards. In connection with the adoption of the 2026 Plan, Aibotics reserved <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260101__20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentySixEquityIncentivePlanMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zyEg21xERB3h" title="Number of shares of common stock">500,000,000 shares of common stock for issuance under the plan, subject to stockholder approval. Shares issued under the 2026 Plan will be, upon issuance, duly authorized, validly issued, fully paid, and non-assessable. Subsequent to December 31, 2025, Aibotics entered into a note purchase agreement pursuant to which it issued a convertible promissory note with an aggregate principal amount of up to approximately $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zv2uNPHugH4d" title="Principal amount">281,250, issued at an original issue discount. The note bears interest at a stated rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zq3jm5Nqlp0d" title="Interest rate">10% per annum and has a maturity of 24 months from issuance. The proceeds from the issuance were intended for general corporate purposes. Subsequent to December 31, 2025, Aibotics issued a promissory note with a principal balance of approximately $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zpn0UelttcWj" title="Principal amount">28,409, which includes an original issue discount of approximately $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zPBjqitmULn7" title="Original issue discount">3,409, for total proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromNotesPayable_c20260101__20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zPUFGnA09gQ4" title="Total proceeds">25,000. The note matures on April 7, 2026 and provides for scheduled principal repayments prior to maturity. The note may be prepaid by the Company at any time without penalty and accrues interest upon the occurrence of an event of default. Subsequent to December 31, 2025, Aibotics issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260101__20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AiboticsIncMember_z8PjVvHMBA3e" title="Number of shares of common stock">25,572,128 shares of its common stock in exchange for total consideration of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zOYaJ3R2EmH3" title="Total consideration">76,716, consisting of $36,358 in cash proceeds, the settlement of $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zKGC3Ux81OA7" title="Accrued interest">38,358 of accrued interest, and the settlement of $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_c20260101__20260515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AiboticsIncMember_zAWwYgHU91I6" title="Settlement of equity issuance costs">2,000 of equity issuance costs.

500000000

281250

0.10

28409

3409

25000

25572128

76716

36358

38358

2000

primarily from the province of Ontario